Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature

Petra Balogh¹, Rita Bánusz², Monika Csóka², Zsófia Váradi², Edit Varga²,³ and Zoltán Sápi¹*

Abstract

Background: Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin and comprises the largest category of soft-tissue sarcomas both in children and adolescents. From a pediatric oncology point of view, RMS has traditionally been classified into alveolar (ARMS) and embryonal (ERMS) subtypes. The anatomical localization of the tumor may vary, but commonly involve the head/neck regions, male and female urogenital tract or the trunk and extremities.

Case presentation: Here, we report two challenging cases involving 17- and 9-years-olds males where diffuse and multiplex bone lesions suggested either a hematological disease or a primary bone tumor (mesenchymal chondrosarcoma). Biopsies, proved a massive infiltration of the bone marrow cavity with rhabdomyosarcoma. In both cases, the ARMS subtype was confirmed using FOXO1 break-apart probes (FISH). Radiological examination could not identify primary soft tissue component in any localization at the time of diagnosis in either cases.

Conclusions: Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS, seems to be a distinct clinico-pathological entity with challenging diagnostic difficulties and different, yet better, biological behavior in comparison to soft tissue ARMS. However, it is difficult to be characterized or predict its prognosis and long-term survival as only sporadic cases (four) were reported so far.

Keywords: Alveolar rhabdomyosarcoma of bone, FOXO-1, Clinico-pathological entity

Background

Rhabdomyosarcoma (RMS) is among the most common soft tissue sarcomas in childhood and adolescence with 4.5 new cases/1 million person/year in the USA and incidences in Europe share similar numbers [1, 2]. It is a high-grade malignancy that primarily involves the head and neck region, the urogenital tract or may develop in soft tissues of the trunk or extremities. Histologically, RMS is comprised of four subtypes; among which embryonal and alveolar RMSs are the most common ones under the age of 20, while pleomorphic and spindle cell variants of the tumor may also occur in adults, with a peak at the 4th-5th and 6th -7th decades of lifetime, respectively. RMS is a high-grade malignancy and the subtype determines the prognosis of the disease. While embryonal RMS has a better outcome (5-year survival rate of 82 %), the alveolar variant of the tumor has a worse prognosis (5-year survival rate of 65 %) which is presumably associated with the cytogenetic aberrations this latter subtype carry [3, 4]. Alveolar RMS can be characterized by a recurrent cytogenetic alteration involving FOXO-1 and PAX3 or PAX7 genes, and the consecutive translocations (t(2;13) or t(1;13) respectively) lead to the excess synthesis of fusion proteins with oncogenic effects [5, 6].

Available data about primary bone ARMS is limited due to the fact that so far only four cases were found in literature reporting fusion-positive alveolar RMS confined to the bone marrow [7–10]. Thus, it is difficult to predict the disease course, the biological behavior and its characteristics. Nonetheless, according to these reports as well as our experiences, primary bone ARMS seems to have a better prognosis and survival rate compared to its soft tissue counterpart. Here we report two...
further cases of primary ARMS of the bone that posed a diagnostic challenge both from a clinical as well as a pathological point of view.

**Case presentations**

**Clinical findings of Case 1**

A 17-year-old male with Crohn’s disease in his medical history, presented with fever, weight loss and lower back pain; experienced over a period of 1–2 weeks. He was found to have elevated inflammatory markers and serious hypercalcemia with impaired renal function. Bone scintigraphy, lumbar spine and pelvic MRI revealed disseminated, diffuse infiltration of the bone marrow which primarily raised the suspicion of lymphoma (Fig. 1a). Repeated bone marrow biopsies (iliac crests) confirmed ARMS (Grade III). A primary soft tissue tumor was never found. During chemotherapy according to CWS-2012 Protocol’s metastatic arm, dose reduction and modifications of cytostatic drugs, intensive care and hemodialysis were required several times due to serious arrhythmias and renal insufficiency caused by osteolysis-induced hypercalcemia. Despite the appropriate, aggressive chemotherapy, his disease showed progression that could be delayed temporarily by RANKL inhibitor denosumab monotherapy for a four month period. We lost him seven months after the initial symptoms.

**Pathological findings of Case 1**

Histological examination of the second bone marrow biopsy (iliac crests) revealed solid sheets of tumor cells infiltrating the entire bone marrow replacing and expelling the normal hematopoietic cells. The highly cellular infiltrate showed no special arrangement, although fine fibro-vascular stroma could focally be identified. The monomorphic, poorly differentiated tumor cells had round, vesicular nuclei with fine chromatin content and were localized at the periphery of the cells, in an eccentric position (Fig. 1b). The cytoplasm of most of the tumor cells possessed either an eosinophilic appearance or abundant intracytoplasmic vacuoles could be seen. While tumor cells did not show striation, the overall morphology suggested rhabdomyoblast-like differentiation (Fig. 1b). Although, by examining a HE specimen, a hematological malignancy could be ruled out, further immunohistochemical (IHC) tests were needed to characterize the phenotype of the tumor cells. The results of IHC showed diffuse vimentin positivity as well as the cells gave substantial cytoplasmic and nuclear labelling with both rhabdomyogen markers, desmin and Myf-4, respectively (Fig. 2a–c). The pan-cytokeratin and TFE-3 reactions were negative as well as INI-1 was retrained; by which alveolar soft part sarcoma or rhabdoid tumor as a differential diagnostic possibility could be ruled out. As the overall pattern of the tumor was not typical for neither embryonal nor alveolar RMS, we further performed a FOXO-1 break-apart FISH probe as the aforementioned gene is known to be involved and is consistently associated with the alveolar subtype of RMS. Indeed, we detected the translocation and break-apart signals involving FOXO-1 (Fig. 2d). Based on the histological and molecular findings as well as extended radiological examinations not proving a primary soft tissue tumor, the diagnosis of primary ARMS (solid variant) of the bone was made.

**Clinical background of Case 2**

A 9-year-old male was admitted to the hospital presented with recurrent fever, lower back and right lower limb pain, experienced over the period of a month. He was found to have mild anemia and elevated inflammatory markers. Imaging studies revealed disseminated multiplex bone lesions involving the entire vertebral column, pelvic bones, ribs, skull, the distal part of the right femur and the proximal part of the right tibia (Fig. 3a). These findings and the lack of primary soft tissue manifestation raised the possibility of Ewing-sarcoma or
malignant lymphoproliferative disease. Initially, the patient required intensive therapy for serious hypercalcaemia and its complications due to osteolysis. The initial histological diagnosis was mesenchymal chondrosarcoma (Grade III), but the atypical clinical findings made histological revision necessary which, in turn, confirmed alveolar rhabdomyosarcoma with bone marrow involvement. A primary soft tissue tumor could not be identified. The therapeutic response was excellent in relation to the first-line chemotherapy given according to CWS-2009 Protocol’s metastatic arm as control MRI and PET/CT revealed complete remission. Seven months after finishing the first-line therapy, a relapse of the primary disease was confirmed, localized to the distal femur and proximal tibia on the right side. Second-line therapy was given according to CWS-2012 relapse protocol and based on the proven ALK-positivity of the tumor, ALK inhibitor crizotinib was permitted as an off-label drug for maintenance therapy for 10 months. In the fourth month of crizotinib treatment multiplex metastases were confirmed. Based on the proven increased mTOR activity of the previous biopsy specimen (iliac crests), mTOR inhibitor temsirolimus was given for 3 months. Due to disease progression, both targeted therapies were stopped and 30 months after the primary diagnosis, we lost the patient.

Pathological findings of Case 2
The biopsy sample that was taken from the tibia showed different morphological patterns and areas that made the overall histological picture misleading: among the bony trabeculae, a cellular tumor infiltrate could be identified and the cells were arranged in solid sheets replacing the normal hematopoiesis. Other foci of the tumor showed intramedullary cartilage islands around which spindle or ovoid shape tumor cells formed a cohesive structure; allowing mesenchymal chondrosarcoma diagnosis. Besides this, however, some areas of the tumor formed solid sheets of tumor islands that were divided by fine fibro-vascular stroma (Fig. 3b–d). The cytomorphology was identical with a so called “small round blue cell tumor”. Considering that neither the age nor the dissemination of the process (multiplex bony lesions) were typical for mesenchymal chondrosarcoma, we further evaluated the phenotype of the tumor cells with several IHC tests. The cells showed cytoplasmic positivity with vimentin as well as intensive and diffuse cytoplasmic desmin and nuclear Myf-4 reactions being observed (Fig. 3e–f). To further characterize the subtype of RMS without an identifiable soft tissue component, we performed a FOXO-1 break apart FISH DNA probe that evaluated the translocation involving FOXO-1. Concerning the clinical and pathological findings, the final diagnosis of primary alveolar rhabdomyosarcoma of the bone was made.

Discussion
Alveolar rhabdomyosarcoma is a high grade neoplasm that has the worst prognosis amongst other subtypes of RMSs (despite combined surgical and chemo/radiotherapy), especially in fusion-positive cases when FOXO-1 gene is involved. It is generally known that the overall outcomes for patients with soft tissue ARMS is worse than in patients with ERMS - even with aggressive multimodal therapy [4]. The prognostic factors defining the outcome of patients with RMS includes the following parameters: patient’s age, site of origin, tumor size, resectability, presence of metastases, number of metastatic sites or tissues involved, presence or absence of regional lymph node involvement, delivery of radiation therapy in selected cases, the unique biological characteristics of RMS tumor cells and, lastly the histological subtype. [11–14]. Regarding the histopathological subtype, there is a significant difference between the 5-year survival with ERMS (82 %) and soft tissue ARMS (65 %) [4]. Besides this, patients with (soft tissue) ARMS who have regional lymph node involvement face a worse outcome (5-year failure-free survival: 43 %) as compared to patients lacking lymph node involvement (5-year failure-free survival: 73 %) [15].

Although the previously reported four cases of primary ARMS (as well as our current two cases) show a better survival rate compared to its soft tissue counterpart, it still causes difficulties in precisely characterizing this tumor type. One reason is the low number of reported
cases, while a major problem alongside this is that even data contained within medical literature is confusing with regards to ARMS classification. It distinguishes fusion-positive and fusion-negative cases; however, there is a tendency that fusion-negative cases should be considered in practical terms ERMS [16]. Until this tendency is not generalized and accepted in routine diagnostic pathology, there will be cases influencing and altering the results exhibited in statistics.

In the case of (soft tissue) alveolar RMS it is known that it commonly infiltrates the bone marrow [17], causing a diagnostic challenge (both in childhood and adult cases), as it can mimic the symptoms of either a hematological malignancy or a primary bone tumor; therefore, biopsy sampling is necessary in each and every case. The most common differential diagnostic problems (considering the localization and/or age) are as follows: Ewing sarcoma, non-Hodgkin lymphoma, mesenchymal
chondrosarcoma and the small cell variant of osteosarcoma. While the morphology of tumor cells are similar (small, round cells), the pattern of infiltration or the accompanying component of the tumor (neoplastic osteoid or hyaline cartilage in small cell variant of OS and mesenchymal chondrosarcoma, respectively) as well as special cytomorphological features such as intracytoplasmic vacuoles or striation of the tumor cells (like in RMS) may sometimes suggest the differentiation lineage. Besides the careful examination of HE stained samples and morphological analysis, ancillary techniques are essential in these cases in order to give a definitive diagnosis. The combination of IHC tests including LCA, vimentin, desmin and CD99 is useful to primarily assess the phenotype of the tumor cells. Although IHC evaluation is sufficient and may lead to a final diagnosis, in most of the cases further molecular examinations such as flow cytometry (especially in hematological diseases) or genetic analysis with regard to gene fusion status (e.g. in Ewing sarcoma and ARMS) are now part of the routine diagnostic panel [18, 19].

The natural history of primary alveolar RMS of bone may show individual variations, but our current cases, together with the other four reported ones [7–10], suggest a better overall prognosis as compared to soft tissue ARMS (Table 1). Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS seems to be a distinct clinico-pathological entity. We wish to stimulate the scientific community into publishing and following-up similar cases. With this proposal, there might be more available data to predict not only the biological behavior and prognosis of the disease, but also to develop and set up further chemotherapeutical combinations that may increase the overall survival of the patients in the future.

**Conclusion**

Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS, seems to be a distinct clinico-pathological entity with challenging diagnostic difficulties and different biological behavior when compared to soft tissue ARMS. More available data might be necessary to predict not only the course of the disease, but also to develop and set up further chemotherapeutical combinations that may increase the overall survival of the patients in the future.

### Table 1 Reported cases of primary alveolar rhabdomyosarcoma of the bone so far without identifiable soft tissue component

| Case       | Reference                  | Age | Sex | Follow-up/survival (months) | Treatment                              | Tumor localization                     |
|------------|----------------------------|-----|-----|----------------------------|----------------------------------------|----------------------------------------|
| 1          | Yamaguchi et al. 2007 [9]  | 14  | m   | 8 (s)                      | -Etoposide                             | Disseminated BM infiltration, not specified |
|            |                            |     |     |                            | -Cyclophosphamide                      |                                        |
|            |                            |     |     |                            | -Pirarubicin                           |                                        |
|            |                            |     |     |                            | -Cisplatin                             |                                        |
|            |                            |     |     |                            | -Vincristine                           |                                        |
| 2          | Jani et al. (2009) [7]     | 16  | m   | 8 (s)                      | -VP16                                  | Disseminated BM infiltration, not specified |
|            |                            |     |     |                            | -Ifofosamide                           |                                        |
|            |                            |     |     |                            | -Vincristine                           |                                        |
|            |                            |     |     |                            | -Adriamycin                            |                                        |
|            |                            |     |     |                            | -Cyclophosphamide                      |                                        |
| 3          | Kern et al. (2015) [10]    | 52  | f   | 12 (s)                     | Not detailed                           | BM infiltration, not specified         |
| 4          | Karagiannis et al. (2015)  | 61  | f   | 7 (f)                      | Topotecan                              | BM infiltration, not specified         |
|            |                            |     |     |                            | -Cyclophosphamide                      |                                        |
|            |                            |     |     |                            | -Vinorelbine (Monotherapy-later)       |                                        |
| 5          | Case 1 (current report)    | 17  | m   | 7 (s)                      | -Ifofosamid                            | Diffuse BM infiltration                |
|            |                            |     |     |                            | -Carboplatin                           |                                        |
|            |                            |     |     |                            | -Etoposid                              |                                        |
|            |                            |     |     |                            | -Vincristin                            |                                        |
| 6          | Case 2 (current report)    | 9   | m   | 30 (s)                     | -Ifofosamid                            | Tibia, femur, pelvic bones, vertebrae  |
|            |                            |     |     |                            | -Etoposid                              |                                        |
|            |                            |     |     |                            | -Carboplatin                           |                                        |
|            |                            |     |     |                            | -Topotecan                             |                                        |

The subtype has been evaluated in each case with molecular diagnostic tools (FISH, Sanger sequencing, spectral karyotyping, cytogenetics).

BM: bone marrow, s: survival, f: follow-up
Abbreviations
ALK: Anaplastic lymphoma receptor tyrosine kinase; ARMS: Alveolar rhabdomyosarcoma; CWS: Cooperative Soft Tissue Study Group; DNA: Deoxyribonucleic acid; ERMS: Embryonal rhabdomyosarcoma; FISH: Fluorescence in situ hybridization; FOXXO-1: Foxhead box protein OT1; HE: Hematoxylin-eosin; IHC: Immunohistochemistry; INI-1: Integrase interactor 1; LCA: Leukocyte common antigen; MRI: Magnetic resonance imaging; mTOR: Mammalian (mechanistic) target or rapamycin; MyF4: Myogenin factor 4; OS: Osteosarcoma; PAX-3/7: Paired box gene 3/7; PCR: Polymerase chain reaction; PET/CT: Positron emission tomography-computed tomography; RANKL: Receptor activator of nuclear factor kappa-B ligand; RMS: Rhabdomyosarcoma; SKY: Spectral karyotyping; TFE3: Transcription factor E3

Acknowledgement
None.

Funding
The authors declare that no funding was used.

Availability of data and material
The radiological and clinical data can be found in the archive of the Department of II. Pediatric Clinic, Semmelweis University. The histological specimens and the corresponding data are belonging to the archive of the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University. The raw data (radiological, clinical, pathological) included in the current manuscript is available upon request for review by the Editor-in-Chief.

Authors’ contributions
PB, ZS participated in the design of the study and histopathological evaluation, and drafted the manuscript. MCS assisted in drafting the manuscript and revised the manuscript. RB, ZSV and EV made contributions in analyzing the corresponding data are belonging to the archive of the 1st Department of II. Pediatric Clinic, Semmelweis University. The histological specimens and the raw data (radiological, clinical, pathological) included in the current manuscript is available upon request for review by the Editor-in-Chief.

Competing interest
The authors declare that they have no competing interests.

Consent for publication
Consent was obtained from the next of kin of the patients (parents) for the publication of the cases and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethical approval and consent to participate
The ethical approval and consent for a case report was waived with the Editor-in-Chief of this journal.

Author details
1 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Úllői út 26, Budapest H-1085, Hungary. 2 2nd Department of Pediatrics, Semmelweis University, Tűzoltó utca 7-9, Budapest H-1094, Hungary. 3 Magnetic Resonance Research Center, Semmelweis University, Tűzoltó utca 7-9, Budapest H-1094, Hungary.

Received: 5 May 2016 Accepted: 8 October 2016
Published online: 18 October 2016

References
1. Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international incidence of childhood cancer. Int J Cancer. 1988;42(4):511–20.
2. Ognjanovic S, Olivier M, Bergermann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers. Cancer. 2012;118(5):1387–96.
3. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM. Rhabdomyosarcoma and undifferentiated sarcoma: the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study. J Pediatr Hematol Oncol. 2003;26(2):165–20.
4. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children’s Oncology Group. J Clin Oncol. 2006;24(24):3844–51.
5. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 1997;94(15):8047–51.
6. Keller E, Arsalan BR, Coiffin CM, El-Bardessy N, DePinho RA, Capechi MR. Alveolar rhabdomyosarcoma in conditional Pax3/Fkhr mice: cooperativity in Ink4a/Arf and Trp53 loss of function. Genes Dev. 2004;18(21):2614–26.
7. Jani P, Charles CY. Massive bone marrow involvement by clear cell variant of rhabdomyosarcoma. Ind J Pediatrics. 2009;76(2):224–8.
8. Karajannis P, Guth N, Thoumiinse GB, Bern C, Sverengerjage J, Oschlies I, Bokeemeyer C, Krapper W, Wardelmann E, Thoumiinse NH. Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT. Clin Sarcoma Res. 2015;5:24. doi:10.1186/s13569-015-0039-6.
9. Yamaguchi K, Koda Y, Suminose A, Sato Y, Matsuaki A, Kanno S, Takimoto T, Suda M, Oda Y, Muto T, Takatsuki H, Haru T. Alveolar rhabdomyosarcoma of unknown origin mimicking acute leukemia at the initial presentation. Rinsho Ketsueki. 2007;48(4):315–20.
10. Kern JB, Hill A, Kruse MJ, Szabo Z, Argani P, Hibbard MK, Gladstone DE, Meyer C, Zheng R, Borowitz MJ, Duffield AS. A leukemic presentation of alveolar rhabdomyosarcoma in a 52-year-old woman without an identifiable primary tumor. Int J Surg Pathol. 2015;23(1):73–7.
11. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13(3):610–30.
12. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Heimann J, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;75(7):1904–22.
13. Brenerman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Pasads CN, Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21(1):78–84.
14. Mandell L, Ghavimi F, LaQuaglia M, Ewby P. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol. 1990;18(6):466–71.
15. Roeberg DA, Garcia-Henriquez N, Lyden ER, et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2011;29(10):1304–11.
16. Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma. Am J Pathol. 2013;180(2):92–99.
17. Kutschek Jr, JF, Parham DM, Kaste SC, Rao BN, Douglass EC, Pratt CB. Embryonal malignancies of unknown primary origin in children. Cancer. 1995;75(1):115–25.
18. Rajvanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009;26(1):1–10.
19. Watther C, Mayrhofer M, Nilsson J, Hofvander J, Jonson T, Madahl N, Ora I, GiSELSON D, MERTENS F. Genetic heterogeneity rhabdomyosarcoma revealed by SNP array analysis. Genes Chromosomes Cancer. 2015;55(1):3–15.